There’s a genuinely good headline for hormone and TRT clinics right now: the FDA is moving to loosen the warnings on testosterone. And I’m a little worried about it, because a good headline is exactly the kind of thing that makes people stop reading right before the part that matters: peptides.

What happened

Two storylines, moving in opposite directions.

On testosterone: the FDA proposed labeling changes that would remove the limitation saying TRT’s safety wasn’t established for age-related low testosterone, and ease the longstanding prostate-cancer warnings. The basis is the TRAVERSE trial, which followed more than 5,000 men and found no meaningful increase in major cardiovascular events.

On peptides: it’s messier, and the rules are being written this summer.

The part everyone’s going to miss

The TRT news is real, and it supports a clear, defensible, on-label conversation with patients. But it’s a proposed labeling change, not a permission slip to get loose. And it tells you nothing about the part of your menu that’s actually in flux.

The legal read: how a peptide actually becomes legal to compound

Here’s the framework most “is BPC-157 legal now?” debates skip.

A compounding pharmacy can use a bulk drug substance in only three situations: (1) it’s the subject of an applicable USP or NF monograph, (2) it’s a component of an FDA-approved drug, or (3) it appears on FDA’s 503A bulks list. Most of the peptides on wellness and longevity menus, BPC-157 and its cousins, clear none of those three cleanly. That’s the whole problem.

On top of that, FDA sorts nominated substances into interim categories: Category 1 (may be eligible; FDA won’t act against compounding while it reviews), Category 2 (significant safety risks; not permitted), and Category 3 (not enough information).

Now the nuance that is very easy to misread: FDA recently removed a batch of peptides, including BPC-157, from Category 2. That sounds like a green light. It isn’t. In several cases the removal happened because the nominations were withdrawn, a procedural move, not an FDA finding that the peptide is safe or eligible. And FDA’s Pharmacy Compounding Advisory Committee meets July 23-24, 2026 to weigh peptides for the 503A list. Translation: the status is “actively being decided,” not “cleared.”

And don’t overstate the TRT side either. The labeling change, if finalized, makes prescribing for age-related hypogonadism easier to defend. It does not remove the need for real evaluation, monitoring, and documentation, and it’s still a proposal.

Now make it about you

If you run TRT and peptides side by side, and a lot of hormone and longevity clinics do, the risk isn’t your testosterone protocol. That one just got a friendlier story. The risk is the peptide sitting right next to it on the menu, where the rules are genuinely unsettled.

What to do with this

• Run each peptide through the three doors. For everything on your menu, ask: USP monograph, component of an approved drug, or on the 503A bulks list? If the honest answer is “none,” that’s your exposure, today.
• Don’t read “off Category 2” as “cleared.” Confirm why it moved. A withdrawn nomination is not a safety clearance.
• Watch the July 23-24 PCAC meeting. The outcome signals which peptides get a 503A pathway and which don’t.
• Lean into the TRT update the right way: clean, documented, on-label TRT workflows, with the improved evidence supporting the conversation. “Looser label” is not “looser standard of care.”

The win is the testosterone label. The trap is assuming the rest of your hormone-and-longevity menu got the same good news. It didn’t.

Real compliance strategy from a real attorney.

Y’all stay protected out there.

---

Want help building a defensible TRT workflow and a clear-eyed read on where each of your peptides actually stands? That’s exactly what we do inside The Protected Practice.

Court Approved Council is owned by Court Approved, PLLC and is not a law firm. Nothing here is legal advice and no attorney-client relationship is formed.